|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500108085 |
|
最近更新日期: Date of Last Refreshed on: |
2025-08-25 10:28:44 |
|
注册时间: Date of Registration: |
2025-08-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
藏地八宝片治疗男性不育的随机对照试验 |
|
Public title: |
A Randomized Controlled Trial of Zangdi Babao Tablets in the Treatment of Male Infertility |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
藏地八宝片治疗男性不育的随机对照试验 |
|
Scientific title: |
A Randomized Controlled Trial of Zangdi Babao Tablets in the Treatment of Male Infertility |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴寒 |
研究负责人: |
胡京美 |
|
Applicant: |
Han Wu |
Study leader: |
Jingmei Hu |
|
申请注册联系人电话: Applicant telephone: |
+86 135 0540 0218 |
研究负责人电话:
Study leader's |
+86 151 6886 3682 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1293107264@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
hujingmei77@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
济南市市中区经六路157号 |
研究负责人通讯地址: |
济南市市中区经六路157号 |
|
Applicant address: |
No.157, Jingliu Street, Shizhong District, Jinan City |
Study leader's address: |
No.157, Jingliu Street, Shizhong District, Jinan City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东大学附属生殖医院 |
||
|
Applicant's institution: |
Hospital for Reproductive Medicine Affiliated to Shandong University |
||
|
研究负责人所在单位: |
山东大学附属生殖医院 |
||
|
Affiliation of the Leader: |
Hospital for Reproductive Medicine Affiliated to Shandong University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2015-140 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东大学附属生殖医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Hospital for Reproductive Medicine Affiliated to Shandong University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-11 00:00:00 | ||
|
伦理委员会联系人: |
朱蕾 |
||
|
Contact Name of the ethic committee: |
Lei Zhu |
||
|
伦理委员会联系地址: |
济南市市中区经六路157号 |
||
|
Contact Address of the ethic committee: |
No.157, Jingliu Street, Shizhong District, Jinan City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 152 5317 8165 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
山东大学附属生殖医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hospital for Reproductive Medicine Affiliated to Shandong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
济南市市中区157号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.157, Jingliu Street, Shizhong District, Jinan City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
山东益衡元健康科技有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shandong Yiheng Yuan Health Technology Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
男性不育 |
||||||||||||||||||||||
|
Target disease: |
Male Infertility |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
临床中精子质量异常(如弱精、畸形精子症)、血清睾酮水平低下是男性不育症的常见病因。藏地八宝片作为复方制剂,前期研究提示其可能改善精子质量及激素水平。本研究拟通过随机安慰剂对照双盲设计,评估其对男性不育患者生殖功能的改善作用,为临床提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
In clinical practice, abnormal sperm quality (such as asthenospermia and teratozoospermia) and low serum testosterone levels are common causes of male infertility. As a compound preparation, preliminary studies have suggested that Zangdi Babao Tablets may improve sperm quality and hormone levels. This study intends to evaluate its effect on improving reproductive function in male infertility patients through a randomized placebo-controlled double-blind design, so as to provide a basis for clinical practice. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 男性,年龄20-45岁; 2. 符合男性不育诊断:未避孕1年未孕,女方检查正常; 3. 基线精子前向运动率<32%; 4. 自愿参与并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Male, aged 20-45 years; 2. Meeting the diagnosis of male infertility: failure to conceive after 1 year of unprotected intercourse, with normal examination results of the female partner; 3. Baseline sperm progressive motility rate < 32%; 4. Voluntarily participating in the study and signing the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1. 先天性生殖系统畸形或后天严重损伤; 2. 肝肾功能异常(ALT/AST>1.5倍正常上限); 3. 近3个月使用过改善精子质量的药物; 4. 对藏地八宝片成分过敏; 5. 合并恶性肿瘤、精神疾病等严重基础病。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Congenital malformation of the reproductive system or severe acquired injury; 2. Abnormal liver or kidney function (ALT/AST > 1.5 times the upper limit of normal); 3. Use of drugs to improve sperm quality in the past 3 months; 4. Allergy to the ingredients of Zangdi Babao Tablets; 5. Complicated with severe underlying diseases such as malignant tumors and mental illnesses. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-01 00:00:00至 To 2027-09-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-01 00:00:00 至 To 2027-09-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用区组随机法,区组长度2-6,按1:1比例由统计软件生成随机序列,录入中央随机数据库,研究者通过数据库获取分组信息 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Block randomization will be adopted with a block length of 2-6. A random sequence will be generated by statistical software at a 1:1 ratio and entered into the central randomization database. Investigators will obtain grouping information through the database. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
对研究参与者、研究者设盲 |
|
Blinding: |
Blinding of research participants and researchers. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
可向研究主持者发送电子邮件获取 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
It can be obtained by sending an email to the study sponsor. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
由临床医生通过门诊途径进行病例招募,由专门CRC人员负责病例记录表填写、数据采集及录入 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Cases will be recruited by clinicians through outpatient services, and dedicated CRC staff will be responsible for filling in case report forms, data collection and entry. (:CRC Clinical Research Coordinator ,,,.) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |